Table 1. Summary of treatment-related adverse effects for nivolumab + ipilimumab therapy and nivolumab and ipilimumab monotherapy.

Adverse effects	Nivolumab + ipilimumab (N=407) [CheckMate-067 (54), -069 (24)]			Nivolumab (N=787) [CheckMate-037 (55), -066 (17), -067]			Ipilimumab (N=357) [CheckMate-067, -069]
	Any grade	Grade 3–4		Any grade	Grade 3–4		Any grade	Grade 3–4
Skin (pruritus, rash, alopecia, vitiligo)	330	30		272	4		254	7
Gastrointestinal (diarrhoea, colitis)	259	79		127	12		163	54
Pulmonary (pneumonitis, dyspnoea)	51	13		14	1		20	1
Endocrine (hypothyroidism, hypophysitis)	73	3		27	0		23	2
Hepatic (raised ALT and AST)	144	62		24	7		27	7
Musculoskeletal (arthalgia, asthenia, myalgia)	52	1		59	0		29	0
Haematological (neutropaenia, thrombocytopaenia, anaemia)	NA	NA		12	2		NA	NA
Miscellaneous (fatigue, pyrexia, headache, chills, nausea and vomiting, increased lipase, constipation, anorexia, abdominal pain, Guillan-Barre syndrome, demyelination, uveitis, transfusion-related reactions, drug hypersensitivity)	557	57		510	13		305	12
Cessation of treatment due to adverse effects	158			31			54